Ionis Pharmaceuticals(IONS) announced that its partner Roche (RHHBY), also known as Genentech in the U.S., has enrolled the first patient in a pivotal study of RG6042, or IONIS-HTTRx, for people living with symptoms of Huntington’s disease, or HD, a hereditary neurodegenerative disorder for which there is currently no approved disease-modifying treatment. RG6042 is the first therapy in pivotal trials designed to target the underlying cause of HD by reducing production of the toxic mutant huntingtin protein, mHTT. Ionis has earned a $35M milestone payment for the initiation of the study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.